DataMeds AI, Inc. (MEDS) is a Tampa-based micro-cap health information technology and pharmacy services company. It operates the EinsteinRx artificial intelligence dispensing platform, the PharmacyChain blockchain-based smart-contract system, the Corexa Health pharmacy division, and Helomics, a clinical molecular diagnostics laboratory. Formerly Wellgistics Health, it adopted the DataMeds AI name and the MEDS symbol in July 2026.
Shares were down 21.62% at $0.58, compared with a prior close of $0.74, confirming a decisive move lower. The immediate driver is verifiable: the company disclosed an at-the-market sales agreement with Dawson James Securities, accompanied by a prospectus supplement covering the resale of shares under an existing shelf registration. Investors read it as the latest chapter in a long-running dilution story.
DataMeds AI entered into an ATM sales agreement allowing it to issue and sell common stock from time to time through Dawson James, acting as agent or principal. Sales can occur on Nasdaq or other trading venues, the company is under no obligation to sell any shares, and it agreed to pay the agent a 3.0% commission on gross proceeds. The shares sit under a shelf registration declared effective in May 2026.
For a company of this size — market capitalization is roughly $3.3 million — the announcement matters less for any single sale than for what it signals: management wants a standing mechanism to raise cash into the market. Because the facility is uncommitted, the market must now price continuous, unpredictable supply above the current bid. That is precisely the setup that compresses a micro-cap's valuation.
The new facility lands on top of an unusually crowded capital structure. A resale registration covers about 34.5 million shares tied to May 2026 convertible notes, PIPE warrants and placement-agent warrants — many multiples of the roughly 4.5 million shares outstanding reported at the end of September. Those instruments carry variable conversion prices that reset toward market, meaning a falling share price mechanically increases the share count.
Earlier in 2026 the company completed a 1-for-50 reverse split to restore Nasdaq bid compliance and regained broader listing compliance in October. But each piece of good news has been accompanied by fresh issuance, and investors have consistently treated equity events as selling catalysts rather than funding milestones.
The move also extends a violent unwind. Third-quarter results published November 13 showed revenue of $2.67 million, up 50% sequentially, and net income of $10.54 million — but that profit was driven almost entirely by a $19.06 million gain on debt extinguishment rather than operations. Shares spiked intraday that Friday to roughly $1.08 before closing at $0.74 on about 4.3 million shares. Monday's session has simply resumed the downtrend, and the ATM disclosure gave sellers a fresh justification.
Volume has been moderate rather than climactic: roughly 157,000 shares changed hands in the first 70 minutes, tracking close to the recent daily average near 190,000 shares and far below Friday's spike. The selling looks orderly and continuous, not a single forced liquidation.
The move is company-specific. It stems from a company filing rather than a sector or macro shock, and it is playing out in one of the least liquid corners of the small-cap healthcare universe. Technically, shares broke below Friday's $0.74 close almost immediately, slid to an intraday low near $0.50, and remain far beneath their 50-day and 200-day moving averages, which still reflect September's elevated prices. The rebound toward $0.58 off the low suggests bargain-hunting interest, but the trend structure remains firmly negative.
The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, meaning transformative news plus an extreme, rare price move. MEDS scores 38 out of 100.
The verified news is genuine and material for a $3.3 million company: a new equity sales facility directly affects share supply and financing risk. But it is a routine instrument for a serial issuer, not a pivotal event. The price move was 21.62%, about 1.7 times the stock's average absolute daily move of roughly 13% across the last 60 sessions. Moves of that size have occurred five times in that window. Strong-but-familiar news combined with a modestly unusual swing produces a mid-range score.
Attention turns to whether DataMeds actually draws on the facility, since any confirmed sales would validate dilution fears. Fourth-quarter and full-year results will be scrutinized for organic revenue durability and for how much of the reported profit was one-off accounting. Management has flagged a launch of the Health Lives Here consumer app, a medical food product, and a non-binding memorandum with a Florida HMO covering more than 25,000 members, with definitive agreements targeted for the fourth quarter. The November 3 termination of the Datavault letter of intent removed one source of share issuance but also removed a headline catalyst. Key risks include continued cash burn, variable-price conversions, and the possibility that the ATM itself caps any rally.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the featured list changes as conditions shift. For traders navigating volatile micro-caps like this one, reviewing the current leaders is a practical starting point.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MEDS moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 27 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The 10-day moving average for MEDS crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MEDS entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDS advanced for three days, in 138 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
MEDS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.423). P/E Ratio (0.000) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MEDS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MEDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors